Download Professor Anthony Chalmers

School of Clinical Sciences
Plenary Research Seminars
Thursday 6th April 2017, 1.00pm – 2.00pm
Professor Anthony
Chalmers
Professor of Clinical Oncology, University of
Glasgow, Chair, NCRI CTRad
Combining DNA damage response
inhibitors with radiotherapy and
temozolomide to improve outcomes for
glioblastoma patients
Seminar Room A&B, Learning & Research Building Level 2, Southmead
Hospital, Bristol BS10 5NB. A light lunch will be available from 12.30pm
Professor Anthony Chalmers is Chair of Clinical Oncology at the University of Glasgow. His clinical practice at
the Beatson West of Scotland Cancer Centre is devoted to the treatment of patients with brain tumours, and he runs the
Translational Radiation Biology laboratory in the Institute for Cancer Sciences. His main research interest is in improving
outcomes for patients with glioblastoma by combining radiotherapy with targeted drug therapies, but his research
interests in radiotherapy-drug combinations extend across tumour sites including lung cancer and mesothelioma. He is
Chief Investigator for a portfolio of early phase clinical trials evaluating the oral PARP inhibitor olaparib in combination
with radiotherapy and/or chemotherapy in treatment of glioblastoma, and also leads the randomised phase II SYSTEMS2 trial of radiotherapy dose escalation in mesothelioma. He is Chair of the UK’s Clinical and Translational Radiotherapy
Research Working Group (CTRad) and is a scientific theme lead for the Radiotherapy-Drug Combinations Consortium
(RaDCom), which is a joint initiative between Cancer Research UK and the UK National Cancer Research Institute.
Hosted by Kathreena Kurian – Reader in Brain Tumour Research/Consultant Neuropathologist .
Learning & Research, Southmead Hospital, BS10 5NB
Staff can contact Rosy Bousfield to arrange transport to/from the venue ([email protected])
Tel +44 (0)117 33 11690
Email [email protected]
bristol.ac.uk/clinical-sciences/